PMID- 27016421
OWN - NLM
STAT- MEDLINE
DCOM- 20171204
LR  - 20181113
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 17
DP  - 2016 Apr 26
TI  - Prognostic implications of PIK3CA amplification in curatively resected 
      liposarcoma.
PG  - 24549-58
LID - 10.18632/oncotarget.8240 [doi]
AB  - BACKGROUND: We investigated the epidemiologic characteristics and prognostic 
      significance of PIK3CA mutations/amplifications in curative resected liposarcoma. 
      PATIENTS AND METHODS: A total of 125 liposarcoma tissue samples were collected 
      over a 12-year period. PIK3CA mutations and gene copy number amplifications were 
      analyzed by pyrosequencing and fluorescence in situ hybridization (FISH). 
      RESULTS: Nine of the 105 liposarcomas (8.6%) had activating PIK3CA mutation. 
      PIK3CA mutations were more frequent in myxoid/round cell and pleomorphic tumors 
      compared with well-differentiated/dedifferentiated tumors (13.3% vs. 2.2%, 
      P=0.043). In FISH PIK3CA analysis, copy number gain was detected in 14 of the 101 
      tumors (13.9%): 11 (10.9%) tumors had increased gene copy number (polysomy) and 3 
      (3.0%) exhibited gene amplification. In survival analysis, patients with PIK3CA 
      copy number gain had a worse prognosis compared to patients without PIK3CA 
      amplification (median disease-free survival [DFS] 22.2 vs. 107.6 months p=0.005). 
      By multivariate analysis, PIK3CA copy number gain was an independent prognostic 
      factor for worse DFS (P=0.027; hazard ratio, 2.400; 95% confidence interval 1.105 
      to 5.213). PIK3CA mutation was not associated with DFS and overall survival. 
      CONCLUSIONS: We demonstrated PIK3CA mutation and amplification in liposarcoma. 
      PIK3CA copy number gain was an independent poor prognostic factor for DFS. 
      Further studies are needed to evaluate the potential diagnostic and therapeutic 
      role of PIK3CA mutations and amplifications in liposarcoma.
FAU - Kim, Joo Hoon
AU  - Kim JH
AD  - Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer 
      Center, Yonsei University College of Medicine, Seoul, Korea.
FAU - Lee, Jae Seok
AU  - Lee JS
AD  - Department of Pathology, Dongguk University College of Medicine, Dongguk 
      University Ilsan Hospital, Goyang, Korea.
FAU - Kim, Eo Jin
AU  - Kim EJ
AD  - Department of Pathology, Dongguk University College of Medicine, Dongguk 
      University Ilsan Hospital, Goyang, Korea.
FAU - Park, Kyu Hyun
AU  - Park KH
AD  - Cancer Metastasis Research Center, Song Dang Institute for Cancer Research, 
      Yonsei University College of Medicine, Seoul, Korea.
FAU - Kim, Ki Hyang
AU  - Kim KH
AD  - Department of Internal Medicine, Busan Paik Hospital, Inje University College of 
      Medicine, Busan, Korea.
FAU - Yi, Seong Yoon
AU  - Yi SY
AD  - Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of 
      Medicine, Ilsan, Korea.
FAU - Kim, Han Seong
AU  - Kim HS
AD  - Department of Pathology, Ilsan Paik Hospital, Inje University College of 
      Medicine, Ilsan, Korea.
FAU - Cho, Yong Jin
AU  - Cho YJ
AD  - Department of Orthopedic Surgery, Yonsei University College of Medicine, Seoul, 
      Korea.
FAU - Shin, Kyoo-Ho
AU  - Shin KH
AD  - Department of Orthopedic Surgery, Yonsei University College of Medicine, Seoul, 
      Korea.
FAU - Ahn, Joong Bae
AU  - Ahn JB
AD  - Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer 
      Center, Yonsei University College of Medicine, Seoul, Korea.
FAU - Hu, Hyuk
AU  - Hu H
AD  - Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
FAU - Kim, Kyung Sik
AU  - Kim KS
AD  - Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
FAU - Choi, Young Deuk
AU  - Choi YD
AD  - Department of Urology, Yonsei University College of Medicine, Seoul, Korea.
FAU - Kim, Sunghoon
AU  - Kim S
AD  - Department of Obstetrics and Gynecology, Yonsei University College of Medicine, 
      Seoul, Korea.
FAU - Lee, Young Han
AU  - Lee YH
AD  - Department of Radiology, Yonsei University College of Medicine, Seoul, Korea.
FAU - Suh, Jin-Suck
AU  - Suh JS
AD  - Department of Radiology, Yonsei University College of Medicine, Seoul, Korea.
FAU - Noh, Sung Hoon
AU  - Noh SH
AD  - Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
FAU - Rha, Sun Young
AU  - Rha SY
AD  - Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer 
      Center, Yonsei University College of Medicine, Seoul, Korea.
FAU - Kim, Hyo Song
AU  - Kim HS
AD  - Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer 
      Center, Yonsei University College of Medicine, Seoul, Korea.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.137 (PIK3CA protein, human)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Class I Phosphatidylinositol 3-Kinases/*genetics
MH  - DNA Copy Number Variations
MH  - Female
MH  - *Gene Amplification
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Kaplan-Meier Estimate
MH  - Liposarcoma/diagnosis/*genetics/surgery
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Prognosis
MH  - Young Adult
PMC - PMC5029721
OTO - NOTNLM
OT  - PIK3CA
OT  - amplification
OT  - liposarcoma
OT  - mutation
COIS- The authors declare no conflict of interest.
EDAT- 2016/03/27 06:00
MHDA- 2017/12/05 06:00
PMCR- 2016/04/26
CRDT- 2016/03/27 06:00
PHST- 2016/01/05 00:00 [received]
PHST- 2016/03/02 00:00 [accepted]
PHST- 2016/03/27 06:00 [entrez]
PHST- 2016/03/27 06:00 [pubmed]
PHST- 2017/12/05 06:00 [medline]
PHST- 2016/04/26 00:00 [pmc-release]
AID - 8240 [pii]
AID - 10.18632/oncotarget.8240 [doi]
PST - ppublish
SO  - Oncotarget. 2016 Apr 26;7(17):24549-58. doi: 10.18632/oncotarget.8240.